Philips has introduced Transcend Plus, the latest evolution of its Epiq CVx and Affiniti CVx cardiovascular ultrasound systems. The platform integrates newly FDA-cleared 2D and 3D imaging enhancements with advanced AI applications, delivering superior sharpness, contrast, and anatomical detail.
With innovations like 2D Auto EF Advanced, the system expands AI capabilities for left ventricular function assessment, reducing operator variability and enabling more accurate, reproducible results. Designed to help cardiology teams work smarter, Transcend Plus supports confident decision-making across echo labs, interventional suites, and outpatient care.
Philips highlights three key benefits of Transcend Plus:
Enhanced image quality
Advanced AI integration
Faster, actionable insights
“Transcend Plus represents a bold leap forward in the evolution of echocardiography, reinforcing our commitment to continuous innovation, empowering clinicians with AI-driven tools that enhance confidence, accelerate decision-making, and elevate care at every stage of the cardiac journey,” said David Handler, business leader, Cardiology Ultrasound at Philips. “Transcend Plus is more than an advancement – it’s a clear statement of Philips’ leadership in cardiovascular ultrasound. Building on the momentum of our original Transcend launch, Transcend Plus brings the full power of AI integration to the forefront, giving clinicians the confidence, speed, and precision they need to lead in cardiac care – today and into the future.”